Cevimeline


Cevimeline
Cevimeline
Systematic (IUPAC) name
2-methyspiro (1,3- oxathiolane- 5,3) quinuclidine
Clinical data
Trade names Evoxac
AHFS/Drugs.com monograph
MedlinePlus a608025
Pregnancy cat. C
Legal status Rx only
Routes Oral
Pharmacokinetic data
Protein binding < 20%
Identifiers
CAS number 107233-08-9 YesY
ATC code N07AX03
PubChem CID 83898
DrugBank APRD00224
ChemSpider 75707 YesY
UNII K9V0CDQ56E YesY
KEGG D07667 YesY
ChEMBL CHEMBL1201267 N
Chemical data
Formula C10H17NOS 
Mol. mass 489.565 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.

Contents

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.[citation needed]

References

  1. ^ Ono M, Takamura E, Shinozaki K, et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277. http://linkinghub.elsevier.com/retrieve/pii/S0002939404001369. 
  2. ^ [1] MedicineNet: Cevimeline. Accessed 10/12/2007

External links